Verus Capital Partners LLC Makes New Investment in Cencora, Inc. $COR

Verus Capital Partners LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 690 shares of the company’s stock, valued at approximately $207,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Voleon Capital Management LP purchased a new position in shares of Cencora in the first quarter valued at approximately $3,111,000. Focus Partners Wealth raised its stake in Cencora by 25.8% in the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after buying an additional 1,171 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Cencora by 947.5% in the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after purchasing an additional 232,539 shares in the last quarter. Martin Capital Partners LLC increased its position in shares of Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after purchasing an additional 2,544 shares in the last quarter. Finally, Fiduciary Alliance LLC purchased a new stake in Cencora in the second quarter valued at approximately $262,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 41,544 shares of company stock valued at $12,230,941 in the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

COR has been the subject of a number of analyst reports. Morgan Stanley set a $330.00 target price on Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. TD Cowen boosted their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday. UBS Group lifted their price target on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Robert W. Baird raised their target price on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Trading Down 0.0%

Shares of Cencora stock traded down $0.02 on Thursday, hitting $363.41. The stock had a trading volume of 33,019 shares, compared to its average volume of 1,533,230. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $366.17. The stock has a 50 day moving average of $318.52 and a 200 day moving average of $301.12. The firm has a market capitalization of $70.46 billion, a P/E ratio of 37.29, a PEG ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is currently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.